Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients

被引:34
作者
Hamzah, Lisa [1 ]
Samarawickrama, Amanda [2 ,3 ]
Campbell, Lucy [1 ]
Pope, Matthew [2 ,3 ]
Burling, Keith [4 ]
Walker-Bone, Karen [5 ]
Gilleece, Yvonne [3 ]
Fisher, Martin [2 ,3 ]
Post, Frank A. [6 ]
机构
[1] Kings Coll London, London SE5 9RJ, England
[2] Brighton & Sussex Med Sch, London, England
[3] Brighton & Sussex Univ Hosp, London, England
[4] Cambridge Univ NHS Trust, London, England
[5] Univ Southampton, Lifecourse Epidemiol Unit, MRC, London, England
[6] Kings Coll Hosp NHS Fdn Trust, London, England
关键词
bone mineral density; HIV; renal tubular dysfunction; tenofovir; ANTIRETROVIRAL THERAPY; MINERAL DENSITY; PHOSPHATE EXCRETION; ABACAVIR-LAMIVUDINE; DISOPROXIL FUMARATE; KIDNEY; INFECTION; TOXICITY; MARKERS; ADULTS;
D O I
10.1097/QAD.0000000000000760
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Tenofovir disoproxil fumarate (TDF) may cause renal tubular dysfunction (RTD) and reduce bone mineral density (BMD). We examined the relationship between RTD and BMD in TDF-exposed HIV-positive men. Design and methods: We analysed urinary retinol-binding protein/creatinine ratio (RBPCR) and fractional excretion of phosphate (FEPO4) to quantify RTD in a cross-sectional sample of randomly selected HIV-positive men at a single tertiary outpatient clinic. BMD at the lumbar spine and hip was measured by dual-energy X-ray absorptiometry. Multivariate logistic regression was used to analyse factors associated with RTD, and linear regression to examine the relationship between RTD and BMD. Results: Of 293 men (mean age 48 years, 94% White ethnicity, median TDF exposure 2.1 years), 22.5% had RBPCR-defined RTD and 12.3% had FEPO4-defined RTD. We observed a negative correlation between RBPCR and BMD at the spine (beta -0.2, P=0.002) and hip (total: beta -0.1, P=0.02; femoral neck: beta -0.1, P=0.02), but not between FePO4 and BMD. In multivariable analyses, RTD defined by more than five-fold elevations in RBPCR was associated with significantly lower BMD of the spine. Conclusion: In HIV-positive patients receiving TDF-containing antiretroviral therapy, RTD was associated with lower BMD of the spine in HIV-positive men. RBPCR quantification may identify patients at increased risk of TDF-associated BMD loss. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1785 / 1792
页数:8
相关论文
共 38 条
[1]   Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram [J].
Barth, JH ;
Jones, RG ;
Payne, RB .
ANNALS OF CLINICAL BIOCHEMISTRY, 2000, 37 :79-81
[2]   Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [J].
Bedimo, Roger ;
Maalouf, Naim M. ;
Zhang, Song ;
Drechsler, Henning ;
Tebas, Pablo .
AIDS, 2012, 26 (07) :825-831
[3]   Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks [J].
Bloch, M. ;
Tong, W. W. Y. ;
Hoy, J. ;
Baker, D. ;
Lee, F. J. ;
Richardson, R. ;
Carr, A. .
HIV MEDICINE, 2014, 15 (06) :373-380
[4]  
Bonnick SL, 2010, CURR CLIN PRACT, P1, DOI 10.1007/978-1-60327-499-9
[5]   Metabolic bone disease in HIV infection [J].
Borderi, Marco ;
Gibellini, Davide ;
Vescini, Fabio ;
De Crignis, Elisa ;
Cimatti, Laura ;
Biagetti, Carlo ;
Tampellini, Livia ;
Re, Maria C. .
AIDS, 2009, 23 (11) :1297-1310
[6]   Analysis of molecular forms of urine Retinol-Binding Protein in Fanconi Syndrome and design of an accurate immunoassay [J].
Burling, Keith A. ;
Cutillas, Pedro R. ;
Church, David ;
Lapsley, Marta ;
Norden, Anthony G. W. .
CLINICA CHIMICA ACTA, 2012, 413 (3-4) :483-489
[7]   Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study [J].
Calmy, Alexandra ;
Fux, Christoph A. ;
Norris, Richard ;
Vallier, Nathalie ;
Delhumeau, Cecile ;
Samaras, Katherine ;
Hesse, Karl ;
Hirschel, Bernard ;
Cooper, David A. ;
Carr, Andrew .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (11) :1746-1754
[8]   Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients [J].
Childs, Kathryn ;
Welz, Tanya ;
Samarawickrama, Amanda ;
Post, Frank A. .
AIDS, 2012, 26 (03) :253-262
[9]   Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study [J].
Cotter, Aoife G. ;
Vrouenraets, Saskia M. E. ;
Brady, Jennifer J. ;
Wit, Ferdinand W. ;
Fux, Christoph A. ;
Furrer, Hansjakob ;
Brinkman, Kees ;
Sabin, Caroline A. ;
Reiss, Peter ;
Mallon, Patrick W. G. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) :1659-1666
[10]  
EASTELL R, 1990, J BONE MINER RES, V5, P1237